These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase. Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and pharmacological evaluation of novel bisindolylalkanes analogues. Song YL; Dong YF; Yang T; Zhang CC; Su LM; Huang X; Zhang DN; Yang GL; Liu YX Bioorg Med Chem; 2013 Dec; 21(24):7624-7. PubMed ID: 24262885 [TBL] [Abstract][Full Text] [Related]
4. Docking studies, synthesis, characterization of some novel oxazine substituted 9-anilinoacridine derivatives and evaluation for their antioxidant and anticancer activities as topoisomerase II inhibitors. Kalirajan R; Kulshrestha V; Sankar S; Jubie S Eur J Med Chem; 2012 Oct; 56():217-24. PubMed ID: 22982526 [TBL] [Abstract][Full Text] [Related]
5. Synthesis of 4β-carbamoyl epipodophyllotoxins as potential antitumour agents. Kamal A; Kumar BA; Suresh P; Juvekar A; Zingde S Bioorg Med Chem; 2011 May; 19(9):2975-9. PubMed ID: 21489802 [TBL] [Abstract][Full Text] [Related]
6. Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives. Zhou Y; Xu X; Sun Y; Wang H; Sun H; You Q Bioorg Med Chem Lett; 2013 May; 23(10):2974-8. PubMed ID: 23566520 [TBL] [Abstract][Full Text] [Related]
8. Insight into eukaryotic topoisomerase II-inhibiting fused heterocyclic compounds in human cancer cell lines by molecular docking. Taskin T; Yilmaz S; Yildiz I; Yalcin I; Aki E SAR QSAR Environ Res; 2012; 23(3-4):345-55. PubMed ID: 22490049 [TBL] [Abstract][Full Text] [Related]
9. Synthesis and topoisomerase II inhibitory and cytotoxic activity of oxiranylmethoxy- and thiiranylmethoxy-chalcone derivatives. Na Y; Nam JM Bioorg Med Chem Lett; 2011 Jan; 21(1):211-4. PubMed ID: 21115246 [TBL] [Abstract][Full Text] [Related]
10. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells. Patra N; De U; Kang JA; Kim JM; Ahn MY; Lee J; Jung JH; Chung HY; Moon HR; Kim HS Eur J Pharmacol; 2011 May; 658(2-3):98-107. PubMed ID: 21376033 [TBL] [Abstract][Full Text] [Related]
11. Synthesis, cytotoxicity, DNA binding and topoisomerase II inhibition of cassiarin A derivatives. Luesakul U; Palaga T; Krusong K; Ngamrojanavanich N; Vilaivan T; Puthong S; Muangsin N Bioorg Med Chem Lett; 2014 Jul; 24(13):2845-50. PubMed ID: 24835201 [TBL] [Abstract][Full Text] [Related]
12. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs. Chen W; Qiu J; Shen YM Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142 [TBL] [Abstract][Full Text] [Related]
13. New derivatives of 11-methyl-6-[2-(dimethylamino)ethyl]-6H-indolo[2,3-b]quinoline as cytotoxic DNA topoisomerase II inhibitors. Luniewski W; Wietrzyk J; Godlewska J; Switalska M; Piskozub M; Peczynska-Czoch W; Kaczmarek L Bioorg Med Chem Lett; 2012 Oct; 22(19):6103-7. PubMed ID: 22944121 [TBL] [Abstract][Full Text] [Related]
14. Topoisomerase inhibitors as anticancer agents: a patent update. Khadka DB; Cho WJ Expert Opin Ther Pat; 2013 Aug; 23(8):1033-56. PubMed ID: 23611704 [TBL] [Abstract][Full Text] [Related]
15. Contemporary challenges in the design of topoisomerase II inhibitors for cancer chemotherapy. Bailly C Chem Rev; 2012 Jul; 112(7):3611-40. PubMed ID: 22397403 [No Abstract] [Full Text] [Related]
16. Synthesis and identification of novel indolo[2,3-a]pyrimido[5,4-c]carbazoles as a new class of anti-cancer agents. Pierce LT; Cahill MM; Winfield HJ; McCarthy FO Eur J Med Chem; 2012 Oct; 56():292-300. PubMed ID: 22910137 [TBL] [Abstract][Full Text] [Related]
17. Novel indolizino[8,7-b]indole hybrids as anti-small cell lung cancer agents: Regioselective modulation of topoisomerase II inhibitory and DNA crosslinking activities. Chang SM; Christian W; Wu MH; Chen TL; Lin YW; Suen CS; Pidugu HB; Detroja D; Shah A; Hwang MJ; Su TL; Lee TC Eur J Med Chem; 2017 Feb; 127():235-249. PubMed ID: 28064078 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of aroylthiourea derivatives of 4-β-amino-4'-O-demethyl-4-desoxypodophyllotoxin as novel topoisomerase II inhibitors. Zhao Y; Ge CW; Wu ZH; Wang CN; Fang JH; Zhu L Eur J Med Chem; 2011 Mar; 46(3):901-6. PubMed ID: 21277655 [TBL] [Abstract][Full Text] [Related]
19. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of novel pyrazoline derivatives containing indole skeleton as anti-cancer agents targeting topoisomerase II. Song Y; Feng S; Feng J; Dong J; Yang K; Liu Z; Qiao X Eur J Med Chem; 2020 Aug; 200():112459. PubMed ID: 32502865 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]